Compare IBEX & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | KMDA |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.1M | 458.6M |
| IPO Year | 2017 | 2013 |
| Metric | IBEX | KMDA |
|---|---|---|
| Price | $30.09 | $9.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $35.00 | $13.00 |
| AVG Volume (30 Days) | ★ 165.3K | 67.7K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.18% |
| EPS Growth | ★ 28.26 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $558,273,000.00 | N/A |
| Revenue This Year | $13.14 | $14.79 |
| Revenue Next Year | $5.67 | $11.38 |
| P/E Ratio | ★ $17.98 | $24.59 |
| Revenue Growth | ★ 9.77 | N/A |
| 52 Week Low | $21.64 | $5.54 |
| 52 Week High | $42.99 | $9.35 |
| Indicator | IBEX | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 56.71 |
| Support Level | $27.70 | $6.69 |
| Resistance Level | $30.63 | $9.35 |
| Average True Range (ATR) | 1.02 | 0.26 |
| MACD | 0.30 | -0.01 |
| Stochastic Oscillator | 82.35 | 63.16 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.